Wednesday, July 14, 2010: Issue #1301 Don’t look now, but biotech darling Dendreon Corp. (NASDAQ:DNDN) is sucking wind. The stock had surged 119% this year on the prospect of receiving FDA approval for its novel prostate cancer treatment, Provenge. But since having that news confirmed on April 29, its shares have slumped by 44%. What gives? Well, you can’t ...